Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy
NCT ID: NCT05842928
Last Updated: 2025-05-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
352 participants
INTERVENTIONAL
2023-03-25
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reduction of Polypharmacy in Elderly People With Multiple Diseases
NCT05526963
OPTImization of Medication by Transdisciplinary Assessment of Drug Treatment in Elderly Hospitalized Patients
NCT05387096
Cooperation for Improved Pharmacotherapy in Home-dwelling Elderly People Receiving Polypharmacy - The COOP Study
NCT02379455
Appropriate Polypharmacy in Older People in Primary Care
NCT04181879
Benefit of a Collaborative Approach to Improve the Quality of Medicines Use in Elderly Inpatients
NCT00279656
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Arm
Intensified and patient-centred cooperation between GPs and pharmacists including patient empowerment
PARTNER intervention
The PARTNER intervention includes the following components:
1. Education for health care professionals
A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations;
B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions;
C) checklist for identification of drug-related problems for pharmacists;
D) tapering support tool to facilitate the selection of tapering schemes;
E) divisibility list for PSA-PIM to support the implementation of tapering schemes;
F) empowerment brochures for patients each focussing on one PSA-PIM subgroup
2. Interprofessional workshop and case conference for GPs and pharmacists
3. Pharmacy visit (brown bag/medication review) including patient empowerment
4. GP practice visit including shared decision making (SDM)
Control Arm
Extended routine care
Control intervention
The control intervention only comprises a pharmacy visit with brown bag review.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PARTNER intervention
The PARTNER intervention includes the following components:
1. Education for health care professionals
A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations;
B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions;
C) checklist for identification of drug-related problems for pharmacists;
D) tapering support tool to facilitate the selection of tapering schemes;
E) divisibility list for PSA-PIM to support the implementation of tapering schemes;
F) empowerment brochures for patients each focussing on one PSA-PIM subgroup
2. Interprofessional workshop and case conference for GPs and pharmacists
3. Pharmacy visit (brown bag/medication review) including patient empowerment
4. GP practice visit including shared decision making (SDM)
Control intervention
The control intervention only comprises a pharmacy visit with brown bag review.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient is capable of giving consent
* GP contact in the quarter prior to inclusion
* Current use of ≥ 5 drugs, including ≥ 1 PSA-PIM (hypnotics, opioids, gabapentinoids, antipsychotics, antidepressants, anticholinergic urospasmolytics) with a treatment duration of ≥ 6 months
* Willingness to select a regular pharmacy for the study period
* Consent to data exchange between GP and community pharmacy
Exclusion Criteria
* Current treatment of pain associated with cancer
* Other serious physical illness or mental distress (e.g. bereavement) that makes participation in the study impossible (according to the GP's assessment)
* Psychiatric illness or addiction that makes participation in the study impossible (according to the GP's assessment)
* Unable to meet the requirements of the study (participation in telephone or written questionnaires, visits to the GP practice or community pharmacy, alone or with the help of caregivers for physical infirmity)
* Current participation in research projects on medication safety or geriatric medicine
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bielefeld University
OTHER
University of Witten/Herdecke
OTHER
University Hospital Heidelberg
OTHER
University Hospital Regensburg
OTHER
Institute for Applied Quality Improvement and Research in Health Care
UNKNOWN
Techniker Krankenkasse
OTHER
Federal Joint Committee
OTHER_GOV
Ludwig-Maximilians - University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tobias Dreischulte
Professor of Clinical Health Services Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tobias Dreischulte, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Institute of General Practice and Family Medicine, University Hospital, LMU Munich, Munich, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Bielefeld
Bielefeld, , Germany
University Hospital, LMU Munich
Munich, , Germany
Witten/Herdecke University
Witten, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01VSF21038
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.